Alzheimers Dement
December 2024
Background: Our research group is currently exploring the potential of Butyric acid (NaB), a Short Chain Fatty Acid (SCFA), as a novel therapeutic agent for Alzheimer's disease (AD).
Methods: In our investigation using the 5xFAD mouse model of AD, we observed that NaB had significant effects on Aβ levels, as well as on associative learning and cognitive functioning. Notably, we recorded a 40% reduction in brain Aβ and a 25% increase in fear response during both cued and contextual testing.
Background: Recently, there has been substantial interest in investigating the role of short-chain fatty acids (SCFAs) and, medium chain fatty acids (MCFA) in the neuroinflammation associated with Alzheimer's disease (AD). Specifically, butyrate (SCFA) and lauric acid (MCFA) have demonstrated potential in alleviating neuroinflammation and reducing toxicity associated with amyloid proteins. Additionally, they have been found to enhance mitochondrial function and reduce neuronal hyperactivity.
View Article and Find Full Text PDFPurpose Of Review: This narrative review evaluates the role of diet in the relationship between depression and Alzheimer's disease (AD).
Recent Findings: AD and depression are often comorbid, and depression appears to independently increase the future risk of AD. Evidence suggests diet influences the risk of both conditions directly and indirectly.
The fermentation of rice dietary fibre was measured by the cell yield, pH, optical density specific growth rate and biomass using nine co-cultures of four probiotics at 0, 6, 24 and 48 h incubation. The results from the fermentation of the soluble, insoluble and total dietary fibre (SDF, IDF, and TDF) of two rice varieties were compared. Overall there was no significant difference (p < 0.
View Article and Find Full Text PDF